News
PSNL
6.68
+5.86%
0.37
Weekly Report: what happened at PSNL last week (0406-0410)?
Weekly Report · 1d ago
Personalis Showcases New Cancer Test To Track Treatment Resistance In Real Time
Benzinga · 1d ago
Personalis debuts Real-Time Variant Tracker data for NeXT Personal MRD at AACR 2026
PUBT · 1d ago
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Barchart · 2d ago
Weekly Report: what happened at PSNL last week (0330-0403)?
Weekly Report · 04/06 10:23
Personalis management to present at Needham Virtual Conference
Reuters · 04/01 20:01
Weekly Report: what happened at PSNL last week (0323-0327)?
Weekly Report · 03/30 10:23
Friday's ETF Movers: SLVR, ARKG
NASDAQ · 03/27 18:18
Weekly Report: what happened at PSNL last week (0316-0320)?
Weekly Report · 03/23 10:20
Personalis names Richard Chen president
TipRanks · 03/17 20:15
*Personalis: Chen Will Continue to Serve as Chief Medical Officer >PSNL
Dow Jones · 03/17 20:07
*Personalis Appoints Dr. Richard Chen as Pres to Further Accelerate MRD Adoption >PSNL
Dow Jones · 03/17 20:01
Personalis promotes Richard Chen to president, keeps him as CMO
Reuters · 03/17 20:00
PERSONALIS APPOINTS DR. RICHARD CHEN AS PRESIDENT TO FURTHER ACCELERATE MRD ADOPTION
Reuters · 03/17 20:00
Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL
Seeking Alpha · 03/16 11:05
Weekly Report: what happened at PSNL last week (0309-0313)?
Weekly Report · 03/16 10:19
Thursday's ETF Movers: XOP, ARKG
NASDAQ · 03/12 16:15
Personalis Announces The Publication Of PREDICT-DNA Study In The Journal Of Clinical Oncology, Showing That Ultrasensitive Molecular Residual Disease Testing With Next Personal Can Perform Better Than Current Standard Approaches In Predicting Patient Outcomes Following Neoadjuvant Therapy
Benzinga · 03/12 10:57
Personalis’ NeXT Personal test shows predictive efficacy in breast cancer
TipRanks · 03/12 10:16
Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk
Reuters · 03/12 10:01
More
Webull provides a variety of real-time PSNL stock news. You can receive the latest news about Personalis through multiple platforms. This information may help you make smarter investment decisions.
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.